Anavex Life Sciences (AVXL) Accumulated Expenses (2018 - 2025)

Anavex Life Sciences has disclosed Accumulated Expenses across 8 years of filings, most recently posting $2.9 million for Q4 2025.

• Accumulated Expenses for Q4 2025 came in at $2.9 million, down 62.14% year-over-year; the trailing twelve-month figure through Dec 2025 was $2.9 million (down 62.14% YoY), and the FY2025 annual result was $3.9 million, down 19.5% from the prior year.
• Accumulated Expenses came in at $2.9 million for Q4 2025 at Anavex Life Sciences, down from $3.9 million in the prior quarter.
• In the past five years, Accumulated Expenses ranged from a high of $9.6 million in Q1 2025 to a low of $1.2 million in Q4 2022.
• The 5-year median for Accumulated Expenses is $5.2 million (2021), against an average of $5.3 million.
• Across the five-year window, Accumulated Expenses plunged 77.08% in 2022 and surged 483.25% in 2023, its largest moves.
• Anavex Life Sciences' Accumulated Expenses stood at $5.5 million in 2021, then slumped by 77.08% to $1.2 million in 2022, then soared by 483.25% to $7.3 million in 2023, then advanced by 6.12% to $7.7 million in 2024, then tumbled by 62.14% to $2.9 million in 2025.
• The last three Accumulated Expenses figures came in at $2.9 million (Q4 2025), $3.9 million (Q3 2025), and $3.9 million (Q2 2025), per Business Quant data.